US010080711B2

(12) **United States Patent**
Khan et al.

(10) **Patent No.: US 10,080,711 B2**
(45) **Date of Patent: *Sep. 25, 2018**

(54) **ANTI-TATAR ORAL CARE COMPOSITIONS PROVIDING CRYSTALLISATION PREVENTION**

(71) Applicant: **The Procter & Gamble Company**, Cincinnati, OH (US)

(72) Inventors: **Golam Faruque Khan**, Loveland, OH (US); **William Michael Glandorf**, Mason, OH (US)

(73) Assignee: **The Procter & Gamble Company**, Cincinnati, OH (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 122 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/932,927**

(22) Filed: **Nov. 4, 2015**

(65) **Prior Publication Data**

US 2016/0120776 A1 May 5, 2016

Related U.S. Application Data

(60) Provisional application No. 62/074,847, filed on Nov. 4, 2014.

(30) **Foreign Application Priority Data**

Dec. 18, 2014 (EP) 14198819
Sep. 28, 2015 (EP) 15187088

(51) **Int. Cl.**
A61K 8/24 (2006.01)
A61K 8/34 (2006.01)
A61Q 11/00 (2006.01)

(52) **U.S. Cl.**
CPC ***A61K 8/24*** (2013.01); ***A61K 8/34*** (2013.01); ***A61Q 11/00*** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,941,926 A 6/1960 Salzmann et al.
3,535,421 A 10/1970 Briner et al.
3,678,154 A 7/1972 Widder et al.
3,737,533 A 6/1973 Moon et al.
3,927,201 A 12/1975 Baines et al.
3,927,202 A 12/1975 Harvey et al.
3,959,458 A 5/1976 Agricola et al.
3,988,433 A 10/1976 Benedict
4,136,163 A 1/1979 Watson et al.
4,138,477 A 2/1979 Gaffar
4,244,931 A 1/1981 Jarvis et al.
4,247,526 A 1/1981 Jarvis et al.
4,323,551 A 4/1982 Parran
4,459,425 A 7/1984 Amano et al.
4,515,772 A 5/1985 Parran, Jr. et al.
4,590,066 A 5/1986 Parran, Jr. et al.
4,661,341 A 3/1987 Benedict et al.
4,684,517 A 8/1987 Clipper et al.
4,775,525 A 10/1988 Pera
4,822,599 A 4/1989 Mitra
4,847,070 A 7/1989 Pyrz et al.
4,885,155 A 12/1989 Parran et al.
5,004,597 A 4/1991 Majeti et al.
5,015,467 A 5/1991 Smitherman
5,180,576 A 1/1993 Winston et al.
5,180,577 A 1/1993 Polefka et al.
5,338,537 A 8/1994 White, Jr.
5,451,401 A 9/1995 Zerby et al.
5,538,714 A 7/1996 Pink et al.
5,622,689 A 4/1997 Lukacovic
5,670,138 A 9/1997 Venema et al.
5,695,745 A * 12/1997 Barton A61K 8/24 424/49
5,733,530 A 3/1998 Bacca et al.
5,849,271 A 12/1998 Lukacovic

FOREIGN PATENT DOCUMENTS

DE 3942644 2/1991
EP 0 097 476 * 4/1984
EP 0309414 A2 3/1989
GB 741315 11/1955
WO WO9319728 10/1993

OTHER PUBLICATIONS

U.S. Appl. No. 14/932,943, filed Nov. 4, 2015, Golam Faruque Khan et al.
"Pyrophosphate and Hexametaphosphate Effects in Vitro Calculus Formation", Arch. Oral Biol., vol. 15, pp. 893-896, (1970).

* cited by examiner

Primary Examiner — Celeste A Roney
(74) *Attorney, Agent, or Firm* — Parker D. McCrary; James Ernest Oehlenschlager

(57) **ABSTRACT**

An oral composition is provided comprising at least 0.5% by weight of the composition of pyrophosphate in an orally acceptable carrier, wherein the pyrophosphate is provided by a mixture of disodium pyrophosphate and tetrasodium pyrophosphate in a ratio from disodium pyrophosphate to tetrasodium pyrophosphate in the range of from 1:0.4 to 1:1.2 and wherein the pH value of the composition is in the range of from 6.0 to 8.0. The oral composition can be used for prevention and control of tartar and/or calculus formation.

19 Claims, No Drawings